[Chinese expert consensus on the management of hemorrhagic complications after hematopoietic stem cell transplantation(2021)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2021 Apr 14;42(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2021.04.002.
Abstract
摘要
相似文献
1
[Chinese expert consensus on the management of hemorrhagic complications after hematopoietic stem cell transplantation(2021)].《造血干细胞移植后出血并发症管理的中国专家共识（2021年版）》
Zhonghua Xue Ye Xue Za Zhi. 2021 Apr 14;42(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2021.04.002.
2
[Chinese expert consensus on the diagnosis and management of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (2022)].《造血干细胞移植后窦性阻塞综合征诊断与管理中国专家共识（2022年版）》
Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):177-183. doi: 10.3760/cma.j.issn.0253-2727.2022.03.001.
3
[Chinese expert consensus on the management of long-term complications after hematopoietic stem cell transplantation (2023)].《造血干细胞移植后长期并发症管理中国专家共识（2023年版）》
Zhonghua Xue Ye Xue Za Zhi. 2023 Sep 14;44(9):717-722. doi: 10.3760/cma.j.issn.0253-2727.2023.09.003.
4
[The Chinese expert consensus on hematopoietic stem cell transplantation for malignant lymphoma(2018)].《中国恶性淋巴瘤造血干细胞移植专家共识（2018年版）》
Zhonghua Zhong Liu Za Zhi. 2018 Dec 23;40(12):927-934. doi: 10.3760/cma.j.issn.0253-3766.2018.12.011.
5
[Chinese expert consensus on the diagnosis and treatment of venous thromboembolism after hematopoietic stem cell transplantation (2022)].《造血干细胞移植后静脉血栓栓塞症诊断与治疗中国专家共识（2022年版）》
Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):184-196. doi: 10.3760/cma.j.issn.0253-2727.2022.03.002.
6
The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China.中国异基因造血干细胞移植后白血病复发的监测、治疗和预防共识。
Cancer Lett. 2018 Dec 1;438:63-75. doi: 10.1016/j.canlet.2018.08.030. Epub 2018 Sep 11.
7
[Chinese expert consensus on allogeneic hematopoietic stem cell transplantation for cerebral adrenoleukodystrophy (2023)].《脑型肾上腺脑白质营养不良异基因造血干细胞移植中国专家共识（2023年版）》
Zhonghua Er Ke Za Zhi. 2024 Mar 25;62(4):303-309. doi: 10.3760/cma.j.cn112140-20231019-00302.
8
[Gynecologic care for women undergoing hematopoietic stem cell transplantation: Chinese expert consensus].造血干细胞移植女性的妇科护理：中国专家共识
Zhonghua Fu Chan Ke Za Zhi. 2022 Jun 25;57(6):401-406. doi: 10.3760/cma.j.cn112141-20211225-00749.
9
[Chinese expert consensus of allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia (2022)].《儿童急性淋巴细胞白血病异基因造血干细胞移植中国专家共识（2022年版）》
Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):793-801. doi: 10.3760/cma.j.issn.0253-2727.2022.10.001.
10
[Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)].《造血干细胞移植后急性移植物抗宿主病诊断与治疗中国专家共识（2024年版）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):525-533. doi: 10.3760/cma.j.cn121090-20240608-00214.
引用本文的文献
1
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.在再生障碍性贫血患者进行异基因干细胞移植时，添加鲁索利替尼以预防标准移植物抗宿主病。
Bone Marrow Transplant. 2024 Jul;59(7):997-1005. doi: 10.1038/s41409-024-02266-7. Epub 2024 Apr 5.
本文引用的文献
1
Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.阿伐曲泊帕用于治疗免疫性血小板减少症和慢性肝病所致血小板减少症。
J Blood Med. 2019 Sep 5;10:313-321. doi: 10.2147/JBM.S191790. eCollection 2019.
2
Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.艾曲波帕治疗异基因造血干细胞移植后血小板减少症。
Biol Blood Marrow Transplant. 2019 Jul;25(7):1320-1324. doi: 10.1016/j.bbmt.2019.01.027. Epub 2019 Jan 30.
3
Efficacy of recombinant factor VIIa for severe bleeding complicated by platelet transfusion refractoriness in patients with hematologic malignancies.重组因子 VIIa 治疗血液恶性肿瘤患者血小板输注无效并发严重出血的疗效。
Thromb Res. 2017 Dec;160:14-18. doi: 10.1016/j.thromres.2017.10.015. Epub 2017 Oct 19.
4
Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.重组人血小板生成素促进血小板植入并改善异基因造血干细胞移植后骨髓增生异常综合征和再生障碍性贫血患者的预后。
Biol Blood Marrow Transplant. 2017 Oct;23(10):1678-1684. doi: 10.1016/j.bbmt.2017.06.010. Epub 2017 Jun 19.
5
Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation.供者特异性抗人白细胞抗原抗体预测亲缘单倍体造血干细胞移植后孤立性血小板减少症的持续时间和不良结局。
J Immunol Res. 2017;2017:1043836. doi: 10.1155/2017/1043836. Epub 2017 Apr 16.
6
Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植患者颅内出血的临床特征及危险因素
Ann Hematol. 2016 Oct;95(10):1637-43. doi: 10.1007/s00277-016-2767-y. Epub 2016 Aug 3.
7
Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia.重组凝血因子VIIa在血小板减少的造血干细胞移植患者胃肠道出血难以控制时的应用。
Pak J Med Sci. 2015 Nov-Dec;31(6):1389-93. doi: 10.12669/pjms.316.8357.
8
Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study.低剂量地西他滨治疗异基因造血干细胞移植后血小板减少症患者：一项初步治疗研究
JAMA Oncol. 2015 May;1(2):249-51. doi: 10.1001/jamaoncol.2014.316.
9
Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant.异基因干细胞移植后危及生命的出血的发生率和危险因素。
Br J Haematol. 2015 Jun;169(5):719-25. doi: 10.1111/bjh.13344. Epub 2015 Mar 26.
10
Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后骨髓血管微环境受损与持续性孤立性血小板减少症之间的关联。
Biol Blood Marrow Transplant. 2014 Aug;20(8):1190-7. doi: 10.1016/j.bbmt.2014.04.015. Epub 2014 May 2.
Zotero 插件